Aligos Therapeutics ALGS
NASDAQ ALGS
$4.96 -0.07 (-1.39%)
At close: Oct 21, 2026 · 4:00 PM EDT

Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2019 - 2026)

Updated

Aligos Therapeutics (ALGS) posted Liabilities and Shareholders Equity of $66.33 million for Q2 2026, down 50.8% from $134.71 million a year earlier but up 2.7% from the prior quarter.

Analysis

Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

At the end of FY2025, Aligos Therapeutics' Liabilities and Shareholders Equity came in at $88.53 million, up 26.3% from FY2024.

  • Annual Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -19.7% (FY2020 to FY2025).
  • In prior years, Aligos Therapeutics' Liabilities and Shareholders Equity was $70.09 million in FY2024 (-53.7%), $151.53 million in FY2023 (+3.3%), $146.69 million in FY2022 (-37.7%) and $235.37 million in FY2021 (-11.3%).
  • Quarterly Liabilities and Shareholders Equity has run from a low of $64.56 million in Q1 2026 to a high of $263.07 million in Q3 2021 over five years.
  • On a year-over-year basis, Liabilities and Shareholders Equity increased in five of the last eight quarters, with an average decline of 8.3%.
  • The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q3 2021, with growth of 185.4%; the weakest was Q1 2026, with a decline of 57.2%.
  • According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $64.56 million (Q1 2026), $88.53 million (Q4 2025) and $109.76 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 142.28 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 201.06 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 135.12 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 129.80 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 122.03 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 115.83 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 95.64 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 49.36 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 201.13 Bn
10 Aligos Therapeutics 52.83 Mn -275.57 Mn - 66.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 66.33 Mn
Mar 31, 2026 64.56 Mn
Dec 31, 2025 88.53 Mn
Sep 30, 2025 109.76 Mn
Jun 30, 2025 134.71 Mn
Mar 31, 2025 150.70 Mn
Dec 31, 2024 70.09 Mn
Sep 30, 2024 88.43 Mn
Jun 30, 2024 108.81 Mn
Mar 31, 2024 127.90 Mn
Dec 31, 2023 151.53 Mn
Sep 30, 2023 85.85 Mn
Jun 30, 2023 106.13 Mn
Mar 31, 2023 121.74 Mn
Dec 31, 2022 146.69 Mn
Sep 30, 2022 164.07 Mn
Jun 30, 2022 182.52 Mn
Mar 31, 2022 210.47 Mn
Dec 31, 2021 235.37 Mn
Sep 30, 2021 263.07 Mn
API Access

Aligos Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ALGS&period=max&api_key=YOUR_API_KEY